U. K. and S. S. C. thank the Institutions of Eminence Scheme in the Banaras Hindu University for research support. S. S. C. thanks the Indian Council of Medical Research for research support. U. K. thanks Vaibhav Jaisawal and Kalika Maheshwari for logistic support and Gaurav Kumar Gupta for project assistance. The American Society of Tropical Medicine and Hygiene (ASTMH) assisted with publication expenses. The American Society of Tropical Medicine and Hygiene has waived the Open Access fee for this COVID-19 article.
Mathieu E et al., 2020. Coronavirus Pandemic (COVID-19). Available at: https://ourworldindata.org/coronavirus. Accessed August 25, 2023.
Kaur U , Bala S , Ojha B , Jaiswal S , Kansal S , Chakrabarti SS , 2022. Occurrence of COVID‐19 in priority groups receiving ChAdOx1 nCoV‐19 coronavirus vaccine (recombinant): a preliminary analysis from North India. J Med Virol 94: 407–412.
Our World in Data , 2023. SARS-CoV-2 Variants in Analyzed Sequences. Available at: https://ourworldindata.org/grapher/covid-variants-area?country=~IND. Accessed August 25, 2023.
National Center for Vector Borne Diseases Control (NCVBDC) , 2022. Dengue/DHF Situation in India. Available at: https://ncvbdc.mohfw.gov.in/index4.php?lang=1&level=0&linkid=431&lid=3715. Accessed August 25, 2023.
Kaur U et al., 2021. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers – first results from India. EClinicalMedicine 38: 101038.
Kaur U , Fatima Z , Maheshwari K , Sahni V , Dehade A , Anju KL , Yadav AK , Kansal S , Jaisawal V , Chakrabarti SS , 2023. Long-term safety analysis of the ChAdOx1-nCoV-19 corona virus vaccine: results from a prospective observational study in priority vaccinated groups in North India. Drug Saf 46: 553–563.
- Search Google Scholar
- Export Citation
Kaur U Fatima Z Maheshwari K Sahni V Dehade A Anju KL Yadav AK Kansal S Jaisawal V Chakrabarti SS 2023. Long-term safety analysis of the ChAdOx1-nCoV-19 corona virus vaccine: results from a prospective observational study in priority vaccinated groups in North India. Drug Saf 46: 553– 563.
Kaur U et al., 2022. Persistent health issues, adverse events, and effectiveness of vaccines during the second wave of COVID-19: a cohort study from a tertiary hospital in North India. Vaccines (Basel) 10: 1153.
World Health Organization , 2022. Dengue and Severe Dengue. Available at: https://www.who.int/health-topics/dengue-and-severe-dengue#tab=tab_1. Accessed August 25, 2023.
Alagarasu K et al., 2021. Serotype and genotype diversity of dengue viruses circulating in India: a multi-centre retrospective study involving the Virus Research Diagnostic Laboratory Network in 2018. Int J Infect Dis 111: 242–252.
Matangkasombut P , Manopwisedjaroen K , Pitabut N , Thaloengsok S , Suraamornkul S , Yingtaweesak T , Duong V , Sakuntabhai A , Paul R , Singhasivanon P , 2020. Dengue viremia kinetics in asymptomatic and symptomatic infection. Int J Infect Dis 101: 90–97.
Centers for Disease Control and Prevention , 2021. Dengue. Available at: https://www.cdc.gov/dengue/index.html. Accessed 25 August 2023.
Nath H , Mallick A , Roy S , Kayal T , Ranjan S , Sengupta S , Sukla S , Biswas S , 2022. COVID-19 serum can be cross-reactive and neutralizing against the dengue virus, as observed by the dengue virus neutralization test. Int J Infect Dis 122: 576–584.
Cheng Y-L , Chao C-H , Lai Y-C , Hsieh K-H , Wang J-R , Wan S-W , Huang H-J , Chuang Y-C , Chuang W-J , Yeh T-M , 2022. Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis. Front Immunol 13: 941923.
Thangamani N , Velmurugan LS , Varadarajan P , Shanmugam S , Ravindran A , 2022. COVID-19 antibody status and its impact on the severity of dengue fever among children: an observational study. Indian J Pediatr 89: 944.
Balasubramani S , Govindaraj V , Agarwal R , Pathania A , Vij A , 2022. COVID-19 antibodies as predictor of severe dengue among hospitalized children with dengue illness in the post-third-wave period of COVID-19 infection in India. J Assoc Physicians India 70: 45–48.
- Search Google Scholar
- Export Citation
Balasubramani S Govindaraj V Agarwal R Pathania A Vij A 2022. COVID-19 antibodies as predictor of severe dengue among hospitalized children with dengue illness in the post-third-wave period of COVID-19 infection in India. J Assoc Physicians India 70: 45– 48.
Phetsouphanh C et al., 2022. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 23: 210–216.
Hatch S , Endy TP , Thomas S , Mathew A , Potts J , Pazoles P , Libraty DH , Gibbons R , Rothman AL , 2011. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 203: 1282–1291.
Rothman AL , 2011. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11: 532–543.
Ferguson N , Anderson R , Gupta S , 1999. The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens. Proc Natl Acad Sci USA 96: 790–794.
Wen J , Shresta S , 2019. Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine? Curr Opin Immunol 59: 1–8.
Dejnirattisai W et al., 2016. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol 17: 1102–1108.
Stettler K et al., 2016. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353: 823–826.
Voysey M et al., 2021. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397: 881–891.
Lopez Bernal J et al., 2021. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 373: n1088.